Coexpression of the HER-2 gene product, p185(HER-2), and epidermal growth factor receptor, p170(EGF-R), on epithelial ovarian cancers and normal tissues

Hybridoma

Volumn 17, Issue 4, 1998, Pages 313-321

  Bast Jr , R C ^a,b,c   Pusztai, L ^a   Kerns, Billie Jo ^b   Macdonald, J A ^b   Jordan, Patrick ^b   Daly, Lee ^b   Boyer, Cinda M ^b   Mendelsohn, John ^a   Berchuck, Andrew ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; ONCOPROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROSTATE; PROTEIN EXPRESSION; SKIN; UTERINE CERVIX;

EID: 0031706616     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1998.17.313     Document Type: Article

References (53)

1. Berchuck A, Rodriguez GC, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC Jr: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991;164:669-674.
2. Mileo AM, Fanuele M, Battaglia F, et al.: Preliminary evaluation of HER-2/neu oncogene and epidermal growth factor receptor expression in normal and neoplastic ovaries. Int J Biol Markers 1992;7:114-118.
3. Wang DP, Konishi I, Koshiyama M, et al.: Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumors of the ovary. Virchows Arch 1992; 421:393-400.
4. Stewart CJ, Owens OJ, Richmond JA, and McNicol AM. Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors. Int J Gynecol Pathol 1992;11:266-272.
5. Berchuk A, Kamel A, Whitaker R, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, et al.: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091.
6. Slamon DJ, Godolphin W, Jones LA, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
7. Bauknecht T, Runge M, Schwall M, and Pfleiderer A. Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol 1988;29:147-157.
8. Kacinski BM, Mayer AG, King BL, Carter D, and Chambers SK. NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecol Oncol 1992;44:245-253.
9. Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, and Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol 1993;168:162-169.
10. Meredith RF, Partridge EE, Alvarez RD, et al.: Intraperitoneal radiotherapy of ovarian cancer with leutetium-177-CC49. J Nuc Med 1996;37:1491-1496.
11. Crippa F, Bolis G, Seregni E, et al.: Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 Mov18; Clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 1995;31A:5:686-690.
12. Valone FH, Kaufman PA, Guyre PM, et al.: Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 1995;13:2281-2292.
13. Juweid M, Sharkey RM, Alavi A, et al.: Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody. J Nucl Med 1997;38:257-260.
14. Hird V, Maraveyas A, Snook D, et al.: Adjuvant therapy of ovarian cancer with radioactive monoclona antibody. Br J Cancer 1993;68:403-406.
15. Valone FH, Kaufman PA, Guyre PM, et al.: Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses her-2/neu. J Hematother 1995;4:471-475.
16. Schmolling J, Reinsberg J, Wagner U, and Krebs D: Anti-TAG-72 antibody B72.3-immunological and clinical effects in ovarian carcinoma. Hybridoma 1997;16:53-58.
17. Yu YH, Crews JR, Cooper K, Ramakrishnan S, Houston LL, Leslie DS, George SL, Lidor Y, Boyer CM, Ring DB, Bast RC Jr: Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. Cancer Res 1990;50:3231-3238.
18. Crews JR, Maier LA, Yu YH, Hester S, O'Briant K, Leslie DS, DeSombre K, George SL, Boyer CM, Argon Y, et al.: A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. Int J Cancer 1992;51:772-779.
19. Baselga J, Norton L, Masui H, et al.: Anti-tumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-1333.
20. Pegram MD, Fiendly BM, Chazin VR, et al.: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-1838.
21. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, and Mendelsohn J: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984;44:1002-1007.
22. Masui H, Kamrath H, Apell G, Houston LL, and Mendelsohn J: Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res 1989;49:3482-3488.
23. Ozawa S, Ueda M, Ando N, Abe O, Minoshima S, and Shimizu N: Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor. Int J Cancer 1989;43: 152-157.
24. Hirota N, Ueda M, Ozawa S, Abe O, and Shimizu N. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res 1989;49: 7106-7109.
25. McKenzie SJ, Marks PJ, Lam T, et al.: Generation and characterization of monoclonal antibodies specific for the human new oncogene product p185. Oncogene 1989;4:543-548.
26. Bjorn MJ, Ring D, and Frankel A: Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res 1985;45:1214-1221.
27. Ring DB, Clark R, and Saxena A: Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2. Mol Immunol 1991;28:915-917.
28. Drebin JA, Link VC, Weinberg RA, and Green MI. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 1986;83: 9129-9133.
29. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, and Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER-2/neu gene product. Cancer Res 1990;50:1550-1558.
30. Tagliabue E, Centis F, Campiglio M, et al.: Selection of monoclonal antibodies which induce internalization and phosphorylation of p185/HER-2 and growth inhibition of cells with HER-2/neu gene amplification. Int J Cancer 1991;47:933-937.
31. Kasprzyk PG, Song SU, Di Fiore PP, and King CR. Therapy of an animal model of human gastric cancer using a combination of anti-erbB2 monoclonal antibodies. Cancer Res 1992;52:2771-2776.
32. Tecce R, Digiesi G, Savarese A, Trizio D, and Natali PG: Characterization of cytotoxic activity of saporin anti-gp185/HER-2 immunotoxins. Int J Cancer 1993;55:122-127.
33. Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, Argon Y, Bast RC Jr: Requirements for the internalization of a murine monoclonal antibody directed against the HER-2 gene product c-erbB-2. Cancer Res 1991;51:5361-5369.
34. Rodriguez GC, Boente MP, Berchuck A, Whitaker RS, O'Briant KC, Xu FJ, Bast RC Jr: The effect of antibodies and immunotoxins reactive with the HER-2/neu proto-oncogene on growth of ovarian and breast cancer cell lines. Am J Obstet Gynecol 1993; 168:228-232.
35. Wels W, Harwerth IM, Mueller M, Groner B, and Hynes NE. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 1992;52:6310-6317.
36. Batra JK, Kasprzyk PG, Bird RE, Pastan I, and King CR. Recombinant anti-erbB2 immunotoxins containing pseudomonas endotoxin. Proc Natl Acad Sci USA 1992;89:5867-5871.
37. De Santes K, Slamon D, Anderson SK, et al.: Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992;52:1916-1923.
38. Tsutsumi Y, Naber SP, DeLellis RA, et al.: Neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissue. Hum Pathol 1990;21: 750-758.
39. Ito K, Sasano H, Ozawa N, Sato S, Silverberg SG, Yajima A: Immunolocalization of epidermal growth factor receptor and c-erbB-2 oncogene product in human ovarian carcinoma. Int J Gynecol Pathol 1992;11:253-257.
40. Stromberg K, Johnson GR, O'Connor DM, et al.: Frequent immunohistochemical detection of EGF-supergene family members in ovarian carcinogenesis. Int J Gynecol Pathol 1994;13:342-347.
41. Meden H, Marx D, Raab T, Kron M, Schauer A, and Kuhn W: EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: Immunohistochemical findings and prognostic value. J Obstet Gynecol 1995;21:167-178.
42. Goff BA, Shy K, Greer BE, Muntz HG, Skelly M, and Gown AM: Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumour necrosis factor alpha in epithelial ovarian cancer. Eur J Gynecol Oncol 1996;17:487-492.
43. Xu F-J, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC Jr: Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 gene product p185. Int J Cancer 1993;53:401-408.
44. Press MF, Hung G, Godolphin W, and Slamon DJ: Sensitivity of HER-2/neu antibodies in archaival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
45. Earp HS, Dawson TL, Li X, et al.: Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 1995;35:115-132.
46. Press MF, Cordon-Cardo C, and Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953-962.
47. Natali PG, Nicotra MR, Bigotti A, et al.: Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990;45:457-461.
48. Maguire HC Jr, Jaworsky C, Cohen JA, Hellman M, Weiner DB, and Greene MI: Distribution of neu (c-erbB2) protein in human skin. J Invest Dermatol 1989;92:786-790.
49. D'Emilia J, Bulovas K, D'Ercole K, Wolf B, Steele G Jr, and Summerhayes IC. Expression of the c-erbB2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 1989;4:1233-1239.
50. Cohen JA, Weiner DB, More KF, et al.: Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185) in normal and transformed epithelial tissues of the digestive tract. Oncogene 1989;4:81-88.
51. Bast RC, Xu F, Yu Y, Crews J, Argon Y, Maier L, Lidor Y, Berchuck A, Bower CM: Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer. Immunol Series 1994;61:23-30.
52. Weis W, Beerli R, Hellman P, et al.: EGF receptor and p185erbB2 specific single-chain antibody toxins differ in their cell killing activity on tumor cells expressing both receptor proteins. Int J Cancer 1995;60:137-144.
53. Fan Z, Mendelsohn J. Therapeutic application of anti-growth factor receptor antibodies. Current Opin Oncol 1998;10:67-73.